Overview

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
H. Lundbeck A/S
Treatments:
Brexpiprazole